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Can we improve early mortality in patients receiving renal The number of new patients starting renal replace-
replacement therapy? ment therapy (RRT) in Scotland has risen relentlessly
Background. Approximately one in eight patients with end- from 61 per million of the population in 1989 to 104 perstage renal disease (ESRD) die within the first three months
million in 1997–1998, with no evidence of slowing in thisof starting renal replacement therapy (RRT). We investigated
upward trend (data from the Scottish Renal Registry).which factors might improve this early mortality.
Methods. We performed a prospective nationwide study of This increase is largely due to a greater number of older
all patients commencing RRT for ESRD in Scotland over one patients and those with comorbid illnesses being ac-
year. Patients were classified according to how they presented
cepted for RRT. Mortality within the first three monthsto start RRT, their burden of comorbid diseases, access pre-
of starting RRT is disproportionately high at betweenpared for dialysis, and duration of care by a nephrologist prior
to commencing RRT. Those factors most strongly associated 6 and 16% [1–4], and represented 32% of the deaths
with death within 90 days of commencing treatment were deter- occurring within the first year of RRT in one series [2]
mined by logistic regression analysis. and 47% of deaths in the first two years of RRT in
Results. Patients with an acute unexpected element to their
another [4]. Such patients, who frequently have pro-presentation for RRT had early mortality rates between 6.0
tracted hospital admissions, place heavy pressures onand 8.9 times greater than those who commenced RRT elec-
tively after a period of care from a nephrologist. Patients in health care resources. Data on early mortality are notori-
high and medium comorbidity risk groups had early mortality ously difficult to collect accurately, especially retrospec-
rates of 4.7 and 2.2 times greater than those in the low-risk tively. Patients may die within a few days of commencinggroup. Low serum albumin had a significant association with
treatment and thus might be difficult to identify. Theearly death. Patients who progressed steadily to ESRD, who
had a planned start to dialysis, and who had mature access distinction between acute and chronic renal failure can
were 3.6 times more likely to survive beyond three months be unclear, and the assessment of comorbidity is difficult
than those with no access; they were, however, also younger after death.
with less comorbidity.
Retrospective studies have nevertheless shown thatConclusions. The factors principally associated with early
the presence of comorbid conditions not only adverselymortality are nonelective presentation for RRT, comorbid ill-
ness, and low serum albumin. Patients cared for by a nephrolo- affects early [3, 5, 6] and longer term survival [4] on
gist before requiring RRT who have mature access have better RRT, but also deters early referral to renal services [7].
short-term survival than those without access. They are also Such studies have also linked a short duration of careyounger with less comorbidity. It may be possible to improve
by a nephrologist prior to starting RRT with both earlyshort-term survival in this “unplanned” group if referred early
to facilitate reducing cardiovascular risk factors and prepara- mortality [8] and greater morbidity at the time of starting
tion for RRT. RRT [9–12].
Many patients present for the first time at the stage
when they require dialysis; the absence of a preparation
period is thus unavoidable. Such patients often have a
heavy burden of comorbid illness that may be in partKey words: Scottish Renal Registry, end-stage renal disease, dialysis,
cormorbidity, serum albumin. responsible for their high mortality rate. There is a need
to establish prospectively which factors influence earlyReceived for publication June 28, 1999
mortality and which of these are amenable to improve-and in revised form November 24, 1999
Accepted for publication January 10, 2000 ment by alteration of clinical practice.
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Table 2. Comorbidity risk stratificationTable 1. Mode of presentation for
renal replacement therapy (RRT)
Group Inclusions
Presentation
Low risk Age ,70 years
with no comorbid illnessPlanned Permanent vascular or peritoneal access ready
for use for first RRT. Medium risk Age 70–80 years
or diabetes mellitus age ,70Unplanned Follow-up by nephrologist for $1 month, steady
progression to end stage, no permanent access. or with vascular, cardiac, pulmonary or liver disease
High risk Age .80 yearsAcute renal failure Presentation with presumed acute renal failure
but failure to recover function. or diabetes age .70 years
or diabetes age ,70 with comorbid diseaseAcute on chronic Follow-up by nephrologist for $1 month, unex-
pected acute deterioration in function to reach or 2 or more of vascular, cardiac, pulmonary or liver
disease 1 ESRDend stage.
End-stage Require RRT within 1 month of presentation or any visceral malignancy
to a nephrologist.
tions into high, medium, or low risk by a previously de-
in RRT, we have determined the major influences on
scribed method (Table 2) [1, 4]. A primary renal diagnosis
death within the first 90 days of RRT.
code was chosen from the list issued by the European
Renal Association–European Dialysis and Transplant
METHODS Association and then grouped into seven categories: glo-
merulonephritis, interstitial disease, diabetes, hyperten-Between October 1, 1997, and September 30, 1998, all
sive nephropathy, atherosclerotic renal disease, otheradult patients starting RRT for end-stage renal disease
multisystem diseases, unknown cause (Appendix). Se-(ESRD) in Scotland’s 11 adult renal units were registered
rum albumin was analyzed using bromocresol green inwhen they started RRT, and their status 90 days after the
all but 17 (3.2%) patients, in whom bromocresol purplestart of treatment was recorded. Patients were identified
was employed.weekly by one of us contacting a liaison person in each
Residual renal function at the start of RRT was as-unit to whom a monthly checklist was circulated to ensure
sessed by estimating creatinine clearance using the for-no patients had been missed. The data routinely collected
mula devised by Cockcroft and Gault [13]. It was notby the Scottish Renal Registry were augmented by data
possible within the confines of this study to measurecollected at each site by a single observer (W.M.) from
residual renal function. Residual renal function was notpatients, case notes, and, where available, renal unit com-
calculated for patients who failed to recover from acuteputer systems, and entered directly on to the registry via
renal failure, because such patients were recruited onlya secure modem. Patients were registered on the day
when considered to be “chronic” and so had receivedthey started RRT (except those failing to recover from
RRT for a period of time, thus lowering their serumpresumed acute renal failure, who were registered when
creatinine levels.the physician caring for them considered they would
require permanent RRT). Patients were prospectively
Statistical analysisentered into five groups according to their mode of pre-
For univariate analyses the chi square, Kruskal Wallis,sentation for RRT (Table 1). Patients in the “acute on
or t-tests were used where appropriate. Logistic regres-chronic” group were those previously diagnosed with
sion analysis was employed for multivariate analyses.chronic renal failure, but in whom an unforeseen addi-
A 5% significance level was employed throughout. Alltional illness or insult to renal function such as a cardiac
event or surgery precipitated a deterioration to end-stage statistical analyses were performed using SPSS for Win-
disease. Thirteen patients who were lost to or defaulted dows version 8.0.
from follow-up by a nephrologist were included in the
unplanned group. A patient said to have “permanent
RESULTSaccess” describes one in whom an arteriovenous fistula/
Five hundred thirty-three patients started RRT forgraft or a Permcath (tunneled semipermanent central
ESRD in Scotland in the year studied (104 per millionvenous cannula) for hemodialysis or a Tenckhoff cathe-
population). One patient received a pre-emptive renalter for peritoneal dialysis was ready for use by the first
transplant and was excluded from further analysis. Sev-RRT. A few patients had a Permcath inserted as tempo-
enty-three patients (13.7%) died within 90 days of start-rary access until a fistula could be arranged. These pa-
ing RRT. The cause of death was cardiac disease in 27tients were grouped as unplanned. Follow-up was mea-
(37%) patients, infection in 11 (15%), malignancy in 7sured in months from the time the patient was first seen
(9.5%), cerebrovascular accident in 6 (8%), and otherby a nephrologist to the time of their first RRT.
Patients were grouped according to comorbid condi- causes in 7 (9.6%). Fifteen (21%) died following with-
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Table 3. Patient characteristics
Cohort 90-day survivors Dead by 90 days P value &
(N 5 532) (N 5 459) (N 5 73) statistical test
Median age years (range) 64.65 (15.6–91.4) 63 (15.6–85.8) 71.1 (21.9–91.4) ,0.001
Kruskal Wallis
Sex male 59.8% 60.3% 56.2% 50.5
x2
Median follow-up months (range) 12 (0–335) 14 (0–335) 1 (0–291) ,0.001
IQR 3–49 IQR 3–52 IQR 0–21 Kruskal Wallis
Median estimated creatinine clearance
mL/min (N 5 468: ARF excluded) 7.97 (1.9–31.2) 7.97 (1.9–22.5) 7.52 (2.9–31.2) 50.8
IQR 6.3–10.3 IQR 6.3–10.2 IQR 5.7–11.9 Kruskal Wallis
Mean serum albumin g/L 35.9 SD 5.64 36.5 SD 5.28 32.1 SD 6.36 ,0.001
t-test
Diabetics % 123 (23.1) 106 (23.1) 17 (23.3) 50.9
x2
Presentation %
Planned 227 (42.7) 220 (47.9) 7 (9.6) ,0.001
Unplanned 129 (24.2) 113 (24.6) 16 (21.9) x2
ARF no recovery 57 (10.7) 38 (8.3) 19 (26)
Acute-on-chronic 63 (11.8) 45 (9.8) 18 (24.7)
ESCRF 56 (10.5) 43 (9.4) 13 (17.8)
First mode of RRT %
Hemodialysis 407 (76.5) 342 (74.5) 65 (89) 50.007
CAPD 117 (22) 109 (23.7) 8 (11) Fisher’s exact
APD 8 (1.5) 8 (1.7) 0
First access for RRT %
Temp. central venous line 281 (52.8) 223 (48.6) 58 (79.5) ,0.001
Tunneled central line 30 (5.6) 26 (5.7) 4 (5.5) x2
A-V fistula/graft 95 (17.9) 92 (20) 3 (4.1)
Tenckhoff catheter 126 (23.7) 118 (25.7) 8 (11)
Primary renal diagnosis %
Glomerulonephritis 70 (13.2) 65 (14.2) 5 (6.8) ,0.001
Interstitial disease 122 (22.9) 117 (25.5) 5 (6.8) x2
Multisystem disease 81 (15.2) 56 (12.2) 25 (34.2)
Hypertensive nephropathy 21 (3.9) 20 (4.4) 1 (1.4)
Secondary GN 28 (5.3) 24 (5.2) 4 (5.5)
Diabetic nephropathy 85 (16) 74 (16.1) 11 (15.1)
Unknown 125 (23.5) 103 (22.4) 22 (30.1)
Risk group %
Low 162 (30.5) 155 (33.8) 7 (9.6) ,0.001
Medium 184 (40.0) 161 (35.1) 23 (31.5) x2
High 186 (29.5) 143 (31.2) 43 (58.9)
Abbreviations are: ARF, acute renal failure; APD, automated peritoneal dialysis; CAPD, continuous automated peritoneal dialysis; ESCRF, end-stage chronic
renal failure; RRT, renal replacement therapy; IQR, interquartile range.
drawal of RRT (in 8 because of advanced cardiac or Table 4. Ninety day mortality according to primary
renal diagnosis groupingischemic peripheral vascular disease). Those patients
who died following the withdrawal of RRT were distrib- Primary renal diagnosis Patients Dead by 90 days (%)
uted evenly between the five modes of presentation. Glomerulonephritis 70 5 (7.1)
Interstitial disease 122 5 (4.1)Univariate analysis revealed that age, comorbidity risk
Multisystem disease 81 25 (30.9)group, mode of presentation, initial access for RRT, ini-
Atherosclerosis 49 15 (30.6)
tial mode of RRT, primary renal diagnosis group, dura- Myelomatosis 14 5 (36.7)
Hypertensive nephropathy 21 1 (4.8)tion of follow-up, and initial serum albumin were all sig-
Secondary GN 28 4 (14.3)nificantly associated with death within 90 days of starting
Diabetic nephropathy 85 11 (12.9)
treatment (Table 3). Four percent of patients with inter- Unknown 125 22 (17.6)
stitial nephritis died within 90 days of starting RRT, rising
to 30% of the multisystem disease group (Table 4). For-
ward stepwise logistic regression analysis, however, dem-
onstrated that the mode of presentation, risk grouping,
and serum albumin concentration were the only factors
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Table 5. Logistic regression multivariate analysis of older, followed-up for a shorter time, had lower serum
factors affecting death by 90 days
albumin levels, had lower residual renal function, had a
Odds 95% CI for higher comorbidity burden, and spent a longer time in
ratio odds ratio Significance P the hospital at the time of initiation of RRT than the
Mode of presentation ,0.0001 planned group (Table 6). Stepwise logistic regression
Unplanned 3.6 1.4–9.3 50.008
analysis was again performed to find out which factorsAcute renal failure 8.9 3.3–23.8 ,0.0001
Acute on CRF 7.9 3.0–20.7 ,0.0001 were predictive of death by 90 days among those patients
ESCRF 6.0 2.2–16.7 50.0006 in the planned and unplanned groups. Comorbidity (P 5
Risk group ,0.001
0.045) and low serum albumin (P 5 0.002) were signifi-Medium 2.2 0.9–5.7 50.09
High 4.7 1.9–11.5 50.0007 cantly associated with a higher probability of death by
Serum albumin 0.90 0.85–0.95 ,0.0001 90 days. Residual renal function (P 5 0.07), diagnosis
Planned presentation and low risk are the reference categories. Abbreviations group (P 5 0.1), and follow-up (P 5 0.5) were not. Patients
are: CRF, chronic renal failure; ESCRF, end-stage chronic renal failure.
in the high- and medium-risk groups were 13.6 and 9.0
times more likely to die than those in the low-risk group.
Each 1 g/L increase in serum albumin concentration re-
duced the risk of death by a factor of 0.9 (Table 7).with a significant effect on mortality within 90 days when
all factors were considered together. Planned presenta-
tion, low-risk group, and a diagnosis of glomerulonephri-
DISCUSSION
tis were used as reference categories against which the
This national prospective study shows the major in-others were compared (Table 5). Relative to those with
fluence of comorbidity on death during the first 90 daysa planned presentation, patients in the unplanned group
of RRT. Those patients in the medium and high comor-were 3.6 times more likely to die within 90 days, those
bidity risk groups were found to be two and almost fivewith unrecovered “acute” renal failure 8.9 times, those
times, respectively, more likely to die within the first 90presenting with acute on chronic renal failure 7.9 times,
days of RRT than those in the low-risk group. Forty-and those presenting at end stage were 6 times more
one (56%) of the 73 patients who died within 90 dayslikely to have died by 90 days of treatment. Patients in
of starting RRT did so as a direct result of either cardiac,the medium-risk group were 2.2 times as likely to die by
cerebral, or peripheral vascular disease, or because RRT90 days compared with low-risk patients. The high-risk
was withdrawn because of advanced cardiac or periph-group had a 4.7-fold greater risk of death. The risk of
eral vascular disease. A further seven patients (9.6%)death by 90 days decreased for each 1 g/L increase in
died from malignant disease.serum albumin. The logistic regression model found that
This study also demonstrates that patients requiringdiagnosis group (P 5 0.07), duration of follow-up (P 5
RRT for ESRD who present with an acute deterioration0.6), first mode of dialysis (P 5 0.8), and access for
in renal function on a background of chronic renal failuredialysis (P 5 0.9) were not significantly associated with
or with unrecovered acute renal failure or at end stagedeath by 90 days after considering the effects of mode
have a worse prognosis than those who have been fol-of presentation, risk group, and serum albumin concen-
lowed-up by a nephrologist and progressed steadily totration.
ESRD. Those patients who had been followed-up by aThe categories we used to define the mode of presenta-
nephrologist but had no dialysis access prepared, andtion for dialysis included some information on the length
hence had an unplanned start to RRT, had 3.6 timesof follow-up; however, the logistic regression model was
the risk of death within the first 90 days of treatmentnot significantly altered by removing the length of follow-
compared with those with a planned start.up from the variables considered. Likewise, if the mode
The fact that patients with an acute element to theirof presentation was omitted from the variables consid-
presentation for dialysis fare worse than those withered, the length of follow-up still did not contribute to
steady progression of their renal disease is perhaps un-the logistic regression model. Diabetes and age are both
derstandable. The reasons for the disparity in survivaltaken into account when assigning a patient to a comor-
between those with and without mature access availablebidity risk group and, therefore, were not added to the
in time to start dialysis are likely to be more complex,logistic regression model.
although again, comorbidity plays a major role. ThisSince the unplanned group comprise the only patients
disparity is of great importance to clinicians caring forin whom there is potential to improve upon preparation
these patients, since it is in these two groups of patientsfor RRT, we compared the planned and unplanned
that they are likely to have an opportunity to intervene.groups. Of the 129 patients with unplanned presentation,
The significantly lower burden of comorbid illness in the12.4% died within 90 days, compared with 3.1% of the
planned group means that they present a more attractive227 patients with a planned start to dialysis (P 5 0.001,
Fisher’s exact test). Patients in the unplanned group were prospect for elective access surgery and probably have
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Table 6. Planned and unplanned presentation groups
“Planned” (N 5 227) “Unplanned” (N 5 129) P value
Median age (range) 59.1 67.2 ,0.001a
(15.6–85.4) (22.5–87.1)
Mean serum albumin g/L 37.9 SD 5.32 35.7 SD 5.06 ,0.001c
Median follow-up months (range) 24 17 50.002a
(1–335) (1–243)
Median estimated creatinine clearance 8.53 7.43
(mL/min) (range) (2.69–22.5) (2.2–25.4) 50.002a
Risk group %
Low 97 (42.7%) 32 (24.8%) 50.002b
Medium 63 (27.8%) 54 (41.9%)
High 67 (29.5%) 43 (33.3%)
Primary renal diagnosis %
Glomerulonephritis 40 (17.6%) 16 (12.4%) 50.2b
Interstitial disease 70 (30.8%) 31 (24%)
Multisystem 36 (15.9%) 30 (23.3%)
Diabetic nephropathy 38 (16.7%) 24 (18.6%)
Unknown 43 (18.9%) 28 (21.7%)
Hospital admission days Median 3 (0–94) Median 9 (0–124) ,0.001a
IQR 0–10 IQR 4–19
a Kruskal Wallis test
b x2 test
c Student’s t-test
Table 7. Multivariate logistic regression analysis: characteristics consideration of access is especially desirable in those
predicting 90-day mortality in patients presenting in planned
patients with comorbid illnesses in whom the creationand unplanned groups
of vascular access may be technically difficult because
Odds 95% CI for Significance of vascular disease. Timely placement of access also con-ratio odds ratio P value
tributes to the shorter duration of in-patient care neces-
Serum albumin 0.88 0.8–0.95 50.002
sary in those with a planned start to RRT.Risk group 50.045
Medium 9.0 1.1–73.6 50.04 We did not find that the duration of care by a nephrolo-
High 13.6 1.7–107.8 50.01 gist prior to RRT had a significant effect on short-term
survival when analyzed in the presence of comorbidity
and presentation that had such profound effects at this
stage. The effect of prior care by a nephrologist on longer
a greater chance of a successful procedure, since the term survival, patient quality of life, and the ability to
failure of dialysis vascular access is associated with age attain recommended hematological and biochemical stan-
and vascular disease [14]. However, 25% of patients in dards remains to be determined. The opportunity to edu-
the unplanned group were also in the low comorbidity cate the patient and their relatives so that they make
risk group, and furthermore, although patients in the informed decisions is important [20] and may improve the
planned group did have a longer window of opportunity quality of life. In addition, patients referred early are more
during which to create access for dialysis, the median likely to choose peritoneal rather than hemodialysis,
period of follow-up in the unplanned group was sufficient which may decrease pressures on scarce resources [21].
for this (17 months). It may be possible to improve early We found serum albumin to be a marker of poor prog-
mortality by focusing on strict blood pressure control nosis. This concurs with other studies in which a low serum
and the modification of other cardiovascular risk factors albumin concentration has been found to be a strong
in order to slow as far as possible not only the progression indicator of poor prognosis in patients starting RRT [22]
of chronic renal failure [15, 16], but also other comorbid as well as those maintained on RRT [23, 24]. It seems
illnesses. The major cause of death across all groups is likely that low serum albumin is a marker of general ill
cardiovascular or vascular disease. The early consider- health. It is also associated with longer hospitalization,
ation of formation of access for dialysis is important to higher readmission rates, and increased mortality in gen-
obviate the need for temporary central venous access. eral medical patients without renal failure [25].
The quality of dialysis achieved using temporary cathe- Previous studies have consistently found that patients
ters is inferior to that achieved with a fistula, and there requiring RRT because of diabetic nephropathy have a
are also have significant morbidity and mortality risks particularly poor prognosis. We found diabetic patients
to comprise 16% of the incident cohort and 16% of thoseboth during placement and subsequently [17–19]. Early
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17 Focal segmental glomerulosclerosis with nephrotic syndrome inwho died within 90 days. The early mortality rate among
adults
diabetics was almost 13%. Patients with interstitial ne- 19 Glomerulonephritis; histologically examined, not given pre-
viouslyphritis and those with hypertensive nephrosclerosis had
the best prognosis, and those with other multisystem Group 2. Interstitial nephropathies
disorders had the worst prognosis. Patients in the “other 20 Pyelonephritis, cause not specified
21 Pyelonephritis associated with neurogenic bladdermultisystem disease” group, which was largely comprised
22 Pyelonephritis due to congenital obstructive uropathy with/of patients with atheromatous renal disease and those without vesico-ureteric reflux
with myelomatosis, had more than twice the early mor- 23 Pyelonephritis due to acquired obstructive uropathy
24 Pyelonephritis due to vesico-ureteric reflux without obstructiontality rate of the diabetic group.
25 Pyelonephritis due to urolithiasisThe incidence of new patients starting RRT in Scot- 29 Pyelonephritis due to other cause
land continues to rise and has not yet reached a steady 30 Interstitial nephritis (not pyelonephritis) due to other cause, or
unspecified (not mentioned below)state. The proportion of patients dying within 90 days
31 Interstitial nephropathy due to analgesic drugsin countries with a higher incidence may be greater. 32 Interstitial nephropathy due to cis-platinum
The factors influencing short-term survival in developed 33 Interstitial nephropathy due to cyclosporine A
34 Lead-induced interstitial nephropathycountries are, however, likely to be the same.
39 Drug-induced interstitial nephropathy not mentioned aboveWe have shown in a prospective study the profound 40 Cystic kidney disease, type unspecified
effect of comorbidity on early death of patients receiving 41 Polycystic kidneys, adult type (dominant)
42 Polycystic kidneys, infantile (recessive)RRT. In addition, we have shown that the way in which
43 Medullary cystic disease, including nephronophthisispatients with ESRD present for RRT is important in 49 Cystic kidney disease, other specified type
predicting early mortality. We have demonstrated a 50 Hereditary/familial nephropathy, type unspecified
51 Hereditary nephritis with nerve deafness (Alport syndrome)group of patients, the “unplanned” group, in whom it
52 Cystinosismight be possible to improve short-term survival by pay- 53 Primary oxalosis
ing close attention to cardiovascular risk factors, thus 54 Fabry disease
59 Hereditary nephropathy, other specified typeminimizing comorbidity, and by timely preparation for
61 Oligomeganephronic hypoplasiaRRT. Further study to elucidate the impact of such inter- 63 Congenital renal dysplasia with/without urinary tract
ventions is warranted. malformation
66 Syndrome of agenesis of abdominal muscles (Prune Belly)
92 Gout nephropathy (urate)ACKNOWLEDGMENTS 93 Nephrocalcinosis and hypercalcemic nephropathy
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E-mail: w.metcalfe@abdn.ac.uk 72 Renal vascular disease due to hypertension (no PRD)
Group 5. Secondary GlomerulonephritisAppendix. ERA-EDTA primary renal diagnosis codes and groupings
73 Renal vascular disease due to polyarteritis
Code Primary renal diagnosis (PRD) 74 Wegener granulomatosis
76 Glomerulonephritis related to liver cirrhosisGroup 1. Primary glomerulonephritis
78 Cryoglobulinemic glomerulonephritis10 Glomerulonephritis; histologically not examined
84 Lupus erythematosus11 Focal segmental glomerulosclerosis with nephrotic syndrome in
85 Henoch-Scho¨nlein purpurachildren
86 Goodpasture syndrome12 IgA nephropathy (proven by immunofluorescence, not code 85)
87 Systemic sclerosis (scleroderma)13 Dense deposit disease, membranoproliferative GN; type II
88 Haemolytic uremic syndrome (including Moschcowitz(proven by immunofluorescence and/or electron microscopy)
syndrome)14 Membranous nephropathy
15 Membranoproliferative GN; type 1 (proven by immunofluores- Group 6. Diabetes
cence and/or electron microscopy—not code 84 or 89) 80 Diabetes glomerulosclerosis or diabetic nephropathy
16 Crescentic (extracapilliary) glomerulonephritis (types I, II, and
III) Group 7. Not known and other
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